Whether a cancer is invasive or non-invasive will determine the treatment choices and how a patient might respond to the treatment he or she receives. Most breast cancers are invasive, but in some cases both invasive and non-invasive cancer can be seen in the same specimen, see [1]. In these cases it is necessary with a tool that can distinguish between the invasive tumor components and the non-invasive tumor components, such as ductal carcinoma in situ (DCIS), so that the biomarker expression, e.g. Ki-67 or ER, within the invasive cancer, can be accurately assessed.
The “Invasive Tumor Detection (PDS)” APP provide means for distinguishing between invasive tumor and non-invasive tumor based on a slide physically double stained (PDS) with the myoepithelial cell nuclear marker p63 in brown and a cytokeratin (CK) tumor marker in red, e.g. CK7/19. With VirtualDoubleStaining™ this APP can be combined with other APPs intended for analysis of biomarker expression within invasive tumor components.